Dual-Action Therapy to Prevent L-DOPA-Induced Dyskinesia
This invention repurposes vilazodone, a serotonin reuptake inhibitor and 5-HT1A partial agonist, for dual-action therapy with L-DOPA to reduce Parkinson’s dyskinesia without diminishing motor benefits, offering a more effective long-term treatment strategy.
Background:
L-DOPA is the gold-standard treatment for Parkinson’s disease, but...